Background State-of-the-art renewal has indicated the improvement of diagnostics of patients with metabolic associated fatty liver disease (MAFLD) and/or type II diabetes mellitus (T2DM) by dissecting the clinical characteristics as well as genomic analysis. However, the deficiency of the characterization of microbial and metabolite signatures largely impedes the symptomatic treatment. Methods For the purpose, we retrospectively analyzed the clinical data of 20 patients with MAFLD (short for "M"), 20 cases with MAFLD and T2DM (short for "MD"), together with 19 healthy donors (short for "Ctr"). Microbial and metabolite analyses were further conducted to explore the similarities and differences among the aforementioned populations based on feces and blood samples, respectively. Results Compared with those in the Ctr group, patients with M or MD revealed multifaceted similarities (e.g., Age, ALP, LDL, BUN) and distinctions in clinical indicators of liver (e.g., BMI, ALT, PCHE, CAP). With the aid of microbial and metabolite analyses as well as bioinformatic analyses, we found that the characteristics of gut microbiota (e.g., abundance, hierarchical clustering, cladogram, species) and lipid metabolism (e.g., metabolite, correlation coefficient and scatter plot) were distinct among the indicated groups. Conclusions The patients with MD revealed multifaceted similarities and distinctions in characteristics of microbiome and metabolites with those in the M and HD groups, and in particular, the significantly expressed microbes (e.g., Elusimicrobiota, Berkelbacteria, Cyanobacteria, Peregrinibacteria) and lipid metabolites (e.g., Lipid-Q-P-0765, Lipid-Q-P-0216, Lipid-Q-P-0034, Lipid-Q-P-0800), which would collectively benefit the clinical diagnosis of MAFLD and T2DM.
基金:
Yunnan Science and Technology Project [L-2017018, 2018NS0100]; Natural Science Foundation of Jiangxi Province [20212BAB216073]; Science and technology projects of Guizhou Province [QKH-J-ZK[2021]-107]; Famous Medical Specialist of "High-level Talent Training Support Program" in Yunnan Province; Natural Science Foundation of Tianjin [19JCQNJC12500]; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences [2019PT320005]; Yunnan Geriatrics Clinical Research Center [202102AA310069]; Jiangxi Provincial Key New Product Incubation Program - Technical Innovation Guidance Program of Shangrao [2020G002]; Reserve Training Project of "Thousand" Project of Health Science and Technology Talents in Kunming [2019-sw-52]; Department of Science and Technology of Shangrao City [2020AB002, 2020 K003, 2021F013]
第一作者机构:[1]Kunming Med Univ, Affiliated Hosp 1, Div Gastroenterol, Kunming 650031, Yunnan, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Kunming Med Univ, Affiliated Hosp 1, Div Gastroenterol, Kunming 650031, Yunnan, Peoples R China[*1]Kunming Med Univ, Affiliated Hosp 1, Div Gastroenterol, Kunming 650031, Yunnan, Peoples R China[2]Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gans, 204 Donggangxi Rd, Lanzhou 730000, Gansu, Peoples R China[*2]Gansu Prov Hosp, Key Lab Mol Diagnost & Precis Med Surg Oncol Gans, 204 Donggangxi Rd, Lanzhou 730000, Gansu, Peoples R China[3]Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, 204 Donggangxi Rd, Lanzhou 730000, Gansu, Peoples R China[*3]Gansu Prov Hosp, NHC Key Lab Diag & Therapy Gastrointestinal Tumor, 204 Donggangxi Rd, Lanzhou 730000, Gansu, Peoples R China[4]Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab Radiat Technol & Biophys, 350 Shushanhu Rd, Hefei 230031, Peoples R China[*4]Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab Radiat Technol & Biophys, 350 Shushanhu Rd, Hefei 230031, Peoples R China
推荐引用方式(GB/T 7714):
Yang Qiuping,Zhang Leisheng,Li Qian,et al.Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus[J].BMC MICROBIOLOGY.2022,22(1):105.doi:10.1186/s12866-022-02526-w.
APA:
Yang, Qiuping,Zhang, Leisheng,Li, Qian,Gu, Man,Qu, Qiu...&Yang, Hongju.(2022).Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus.BMC MICROBIOLOGY,22,(1)
MLA:
Yang, Qiuping,et al."Characterization of microbiome and metabolite analyses in patients with metabolic associated fatty liver disease and type II diabetes mellitus".BMC MICROBIOLOGY 22..1(2022)